Katie Swicegood Fulp is a bit of a late arrival to the world of pharma marketing. | In a Q&A for Fierce Pharma Marketing’s ...

With its biosimilars business thriving, Amgen isn’t a fan of changes proposed by HHS Secretary Robert F. Kennedy Jr. | With its biosimilars business thriving, Amgen isn’t a fan of changes proposed by ...

UCB has scored an FDA approval for ultra-rare disease treatment Kygevvi, continuing the positive momentum for the Belgian ...

The Trump administration has spent much of this year working to coerce drugmakers into lowering their prices in the U.S. | ...

Eli Lilly is going for gold at the Milano Cortina 2026 Olympic and Paralympic Winter Games. | Eli Lilly is going for gold at ...

Taking a closer look at the numbers, Comirnaty sales slipped 19% globally to $1.15 billion, the Prevnar franchise experienced a 3% global sales decline to $1.7 billion, and Abrysvo’s performance ...

Insulet is taking diabetes awareness into the workplace. Having found 79% of people with diabetes have faced bias or ...

A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.

One key figure, however, indicates otherwise as sales for Journavx were at $20 million for the period, coming up $3 million ...

Arcutis tapped the mother-daughter duo to discuss their experiences in the “Free to Be Me” campaign. The goal, according to the company, is to show the emotional and physical burden of inflammatory ...

Teva has issued a voluntary recall of more than 500,000 bottles of the widely used blood pressure medication prazosin ...

During the industry’s onshoring rush of the last nine months, Eli Lilly has been among the most aggressive biopharma compa | Eli Lilly is allotting $3 billion to establish an oral medicines ...